Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
Cytokinetics, Incorporated (CYTK): A Bull Case Theory [Yahoo! Finance]
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.
Cytokinetics' heart drug hits market after FDA approval [FOX Business Network]
Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.